Uridine triacetate
| Clinical data | |
|---|---|
| Trade names | Vistogard, Xuriden |
| Routes of administration | Oral granules |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Pyrimidine catabolic pathway |
| Onset of action | Tmax = 2-3 hours |
| Biological half-life | 2-2.5 hours |
| Excretion | Renal |
| Chemical data | |
| Formula | C15H18Cl0N2O9S0 |
| Molar mass | 370.31 g·mol−1 |
Uridine triacetate is a drug used in the treatment of hereditary orotic aciduria[1] and to treat patients following an overdose of chemotherapy drugs 5-fluorouracil or capecitabine, or in patients exhibiting early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of 5-fluorouracil or capecitabine administration.[2][3]
Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics and it is marketed in USA by BTG. Also, It was granted breakthrough therapy designation by FDA in 2015.
References
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION OF XURIDEN
- ↑ BTG Announces FDA Approval of VISTOGARD® (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine
- ↑ "FDA Approved Drugs:Uridine Triacetate". FDA. 2015-12-11. Retrieved 2016-04-29.
This article is issued from Wikipedia - version of the Saturday, April 30, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.